Scott & White Memorial Hospital and Clinics, 2401 South 31st Street, Temple, TX 76508, USA.
Curr Hypertens Rep. 2010 Aug;12(4):233-42. doi: 10.1007/s11906-010-0125-3.
It is currently accepted that hypertension, atherosclerosis, and diabetes are disorders with subtle or overt activation of inflammatory mediators. Therefore, it has become increasingly important to ascertain whether current antihypertensive drug families have proinflammatory or anti-inflammatory actions that modify the outcomes of their hemodynamic effects on blood pressure. We review the current state of knowledge about the effects of the major classes of available antihypertensive agents on inflammation and speculate on the possible contribution of these effects to observations in clinical trials. We suggest that a strategy of drug development specifically addressing inflammation in hypertension may provide increased benefit in terms of target organ damage, and we describe some examples of these promising developments.
目前人们普遍认为，高血压、动脉粥样硬化和糖尿病是存在轻微或明显炎症介质激活的疾病。因此，确定当前抗高血压药物家族是否具有抗炎或促炎作用，从而改变其对血压的血流动力学效应的结局，变得越来越重要。我们回顾了关于现有抗高血压药物主要类别的抗炎作用的现有知识状态，并推测这些作用可能对临床试验中的观察结果产生影响。我们认为，针对高血压中的炎症的药物开发策略可能会在靶器官损伤方面带来更大的益处，并描述了这些有前景的发展的一些例子。
